Cargando…

The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership

China has the world’s second largest burden of multidrug-resistant tuberculosis (MDR-TB; resistance to at least isoniazid and rifampicin), with an estimated 57,000 cases (range, 48,000–67,000) among notified pulmonary TB patients in 2015. During October 1, 2006–June 30, 2014, China expanded MDR-TB c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lixia, Li, Renzhong, Xu, Caihong, Zhang, Hui, Ruan, Yunzhou, Chen, Mingting, Wang, Dongmei, Dirlikov, Emilio, Du, Xin, Zhao, Jin, Zhao, Yanlin, Wang, ShengFen, Liu, Yuhong, Li, Liang, Falzon, Dennis, Sun, Yanni, Wang, Yu, Schwartländer, Bernhard, Scano, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476250/ https://www.ncbi.nlm.nih.gov/pubmed/28628669 http://dx.doi.org/10.1371/journal.pone.0177536

Ejemplares similares

The Global Fund in China: success beyond the numbers
por: Minghui, Ren, et al.
Publicado: (2015)

Cost–effectiveness of a comprehensive programme for drug-resistant tuberculosis in China
por: Fitzpatrick, Christopher, et al.
Publicado: (2015)

Practical Experiences of Delivering Multidrug-Resistant Tuberculosis Comprehensive Supportive Care Services in China
por: Ruan, Yunzhou, et al.
Publicado: (2021)

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China
por: Xia, Hui, et al.
Publicado: (2020)

A pilot study: VereMTB detection kit for rapid detection of multidrug-resistant mycobcterium tuberculosis in clinical sputum samples
por: Ou, Xichao, et al.
Publicado: (2020)

Is knowledge retained by healthcare providers after training? A pragmatic evaluation of drug-resistant tuberculosis management in China
por: Wu, Shishi, et al.
Publicado: (2019)

Programmatic Challenges in Managing Multidrug-Resistant Tuberculosis in Malawi
por: Charlie, Loveness, et al.
Publicado: (2021)

Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
por: Xu, Caihong, et al.
Publicado: (2019)

Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant Mycobacterium tuberculosis in China
por: Song, Zexuan, et al.
Publicado: (2023)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Guiding Tuberculosis Control Through the Healthy China Initiative 2019−2030
por: Zhang, Hui, et al.
Publicado: (2020)

Underreporting of Notifiable Pulmonary Tuberculosis Cases to the National Tuberculosis Information Management System — China, 2015
por: Li, Tao, et al.
Publicado: (2020)

Socially responsible investing through the equity funds in the global ownership network
por: Mizuno, Takayuki, et al.
Publicado: (2021)

Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013
por: Xia, Hui, et al.
Publicado: (2021)

Multichannel Financing Reduces Economic Burden and Improves the Medical Security Level for Tuberculosis Patients
por: Huang, Fei, et al.
Publicado: (2020)

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience
por: Sinkou, Heorhi, et al.
Publicado: (2017)

Clinically prevalent mutations in Mycobacterium tuberculosis alter propionate metabolism and mediate multidrug tolerance
por: Hicks, Nathan D., et al.
Publicado: (2018)

Deconstructing programmatic assessment
por: Wilkinson, Tim J, et al.
Publicado: (2018)

Programmatically Selected Multidrug-Resistant Strains Drive the Emergence of Extensively Drug-Resistant Tuberculosis in South Africa
por: Müller, Borna, et al.
Publicado: (2013)

Effectiveness of the Integrated TB Surveillance System — China, 2018–2019
por: Wang, Ni, et al.
Publicado: (2020)

Making Performance-Based Funding Work for Health
por: Low-Beer, Daniel, et al.
Publicado: (2007)

On the issue of costs in programmatic assessment
por: van der Vleuten, Cees P. M., et al.
Publicado: (2016)

COVID‐19 and programmatic assessment
por: Bala, Laksha, et al.
Publicado: (2020)

Study on the ownership balance and the efficiency of mixed ownership enterprises from the perspective of heterogeneous shareholders
por: Yin, Zhujia, et al.
Publicado: (2018)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study
por: Zhang, Yang, et al.
Publicado: (2017)

Experiential ownership and body ownership are different phenomena
por: Liang, Caleb, et al.
Publicado: (2021)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Programmatic access to file syncing services
por: OWEN, Patrick Haworth
Publicado: (2014)

Strategic and programmatic orientations, 1999-2002 /
Publicado: (1999)

National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
por: Ou, Xichao, et al.
Publicado: (2021)

General Suspended Printing Strategy toward Programmatically Spatial Kevlar Aerogels
por: Cheng, Qingqing, et al.
Publicado: (2022)

Body ownership and experiential ownership in the self-touching illusion
por: Liang, Caleb, et al.
Publicado: (2015)

Financial Burden of Tuberculosis Patients — China, 2020
por: Xu, Caihong, et al.
Publicado: (2023)

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort
por: Sagwa, Evans L., et al.
Publicado: (2015)

The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China
por: Weerasuriya, Chathika K, et al.
Publicado: (2021)

The Ownership of Sanatoria
Publicado: (1899)

Ownership of Prescriptions
Publicado: (1911)

Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing
por: Xia, Hui, et al.
Publicado: (2022)

Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China
por: Weerasuriya, Chathika K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ut5s0kh7nom1fq4uk002rqu8hj